Publicação
Ten Years of CERAB for Complex Aortoiliac Occlusive disease
| Resumo: | INTRODUCTION: Covered Endovascular Aortic Repair (CERAB) has previously been shown to be a viable treatment option for patients with aortiliac occlusive disease. However, data reporting on the technique is still scarce, and durability remains a concern. The aim of this study was to conduct a descriptive analysis of our experience and to evaluate the outcomes of CERAB over the last 10 years. METHODS: A retrospective, single- centre cohort study was conducted. From April 2015 to February 2025, we included all consecutive patients who underwent CERAB for aortiliac occlusive disease. Outcomes were defined as primary patency rate, freedom from clinically driven target lesion revascularisation, and amputation- free survival at 12 and 36 months. Major adverse events were defined as a composite of myocardial infarction, stroke, bowel ischemia, respiratory insufficiency, acute limb ischemia or access- related complications. RESULTS: A total of 23 patients (65%)(65%) male) were included, with a mean age of 60.7 years (±10.2)(±10.2) . The most common clinical presentation was Rutherford classification grade 5 chronic ischemia (44%)(44%) , and the majority (87%)(87%) had Transatlantic Inter- Society Consensus II (TASC II) D lesions. Technical success was achieved in 100%100% of cases. Major adverse events at 30 days were observed in 39%39% , with access- related complications the most common (17%)(17%) . The median hospital stay was six days (range 3.0- 15), and 30- day mortality occurred in one case. The median follow- up was 27 months (4.6- 62.1). The primary patency rate was 84%84% and 77%77% at 12 and 36 months, respectively. The target lesion revascularisation freedom rate was 85%85% at 12 and 36 months, while the major amputation- free survival rate was 89%89% at the same time points. CONCLUSION: The CERAB technique appears to be a feasible option for patients with extensive aortiliac occlusive disease, including TASC II D lesions, demonstrating high technical success. Despite the small sample size, good mid- term outcomes were observed in a clinical and anatomically complex group of patients. |
|---|---|
| Autores principais: | Magalhães, Tiago |
| Outros Autores: | Fernandes e Fernandes, Ruy; Gouveia e Melo, Ryan; Passos, Carolina; Mendes Pedro, Luís |
| Assunto: | Aortoiliac disease CERAB Kissing stent Peripheral arterial disease |
| Ano: | 2026 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | unknown |
| Instituição associada: | Sociedade Portuguesa de Angiologia e Cirurgia Vascular |
| Idioma: | inglês |
| Origem: | Angiologia e Cirurgia Vascular |
| Resumo: | INTRODUCTION: Covered Endovascular Aortic Repair (CERAB) has previously been shown to be a viable treatment option for patients with aortiliac occlusive disease. However, data reporting on the technique is still scarce, and durability remains a concern. The aim of this study was to conduct a descriptive analysis of our experience and to evaluate the outcomes of CERAB over the last 10 years. METHODS: A retrospective, single- centre cohort study was conducted. From April 2015 to February 2025, we included all consecutive patients who underwent CERAB for aortiliac occlusive disease. Outcomes were defined as primary patency rate, freedom from clinically driven target lesion revascularisation, and amputation- free survival at 12 and 36 months. Major adverse events were defined as a composite of myocardial infarction, stroke, bowel ischemia, respiratory insufficiency, acute limb ischemia or access- related complications. RESULTS: A total of 23 patients (65%)(65%) male) were included, with a mean age of 60.7 years (±10.2)(±10.2) . The most common clinical presentation was Rutherford classification grade 5 chronic ischemia (44%)(44%) , and the majority (87%)(87%) had Transatlantic Inter- Society Consensus II (TASC II) D lesions. Technical success was achieved in 100%100% of cases. Major adverse events at 30 days were observed in 39%39% , with access- related complications the most common (17%)(17%) . The median hospital stay was six days (range 3.0- 15), and 30- day mortality occurred in one case. The median follow- up was 27 months (4.6- 62.1). The primary patency rate was 84%84% and 77%77% at 12 and 36 months, respectively. The target lesion revascularisation freedom rate was 85%85% at 12 and 36 months, while the major amputation- free survival rate was 89%89% at the same time points. CONCLUSION: The CERAB technique appears to be a feasible option for patients with extensive aortiliac occlusive disease, including TASC II D lesions, demonstrating high technical success. Despite the small sample size, good mid- term outcomes were observed in a clinical and anatomically complex group of patients. |
|---|